Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RUBY
Previous Symbol
CUSIPN/A
Phone617-679-9600
Debt
Debt-to-Equity Ratio0.06
Current Ratio25.78
Quick Ratio25.78
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees83
Outstanding Shares79,040,000
Market Cap$1.35 billion
OptionableNot Optionable
Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions
What is Rubius Therapeutics' stock symbol?
Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."
How were Rubius Therapeutics' earnings last quarter?
Rubius Therapeutics Inc (NASDAQ:RUBY) issued its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.06. View Rubius Therapeutics' Earnings History.
When is Rubius Therapeutics' next earnings date?
What price target have analysts set for RUBY?
4 analysts have issued 1-year price targets for Rubius Therapeutics' stock. Their forecasts range from $37.00 to $40.00. On average, they anticipate Rubius Therapeutics' stock price to reach $38.50 in the next year. This suggests a possible upside of 125.7% from the stock's current price. View Analyst Price Targets for Rubius Therapeutics.
What is the consensus analysts' recommendation for Rubius Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rubius Therapeutics.
Has Rubius Therapeutics been receiving favorable news coverage?
Press coverage about RUBY stock has been trending positive on Sunday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Rubius Therapeutics earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an impact on the company's share price in the near term.
Who are some of Rubius Therapeutics' key competitors?
Some companies that are related to Rubius Therapeutics include Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Regenxbio (RGNX), Spark Therapeutics (ONCE), Editas Medicine (EDIT) and Autolus Therapeutics (AUTL).
Who are Rubius Therapeutics' key executives?
Rubius Therapeutics' management team includes the folowing people:
- Mr. David R. Epstein, Exec. Chairman (Age 56)
- Dr. Torben Lauesgaard Straight Nissen, Pres (Age 46)
- Dr. Christopher L. Carpenter M.D., Ph.D., Chief Medical Officer (Age 62)
- Dr. Pablo J. Cagnoni, CEO & Director (Age 55)
- Dr. Avak Kahvejian, Co-Founder and Chief Innovation Officer
When did Rubius Therapeutics IPO?
(RUBY) raised $200 million in an initial public offering on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.
When does Rubius Therapeutics' lock-up period expire?
Rubius Therapeutics' lock-up period expires on Monday, January 14th. Rubius Therapeutics had issued 10,483,000 shares in its initial public offering on July 18th. The total size of the offering was $241,109,000 based on an initial share price of $23.00. After the expiration of Rubius Therapeutics' lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
Who are Rubius Therapeutics' major shareholders?
Rubius Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (7.88%), Baillie Gifford & Co. (4.95%), Artal Group S.A. (3.68%), Capital World Investors (3.66%), Alliancebernstein L.P. (2.06%) and BlackRock Inc. (2.01%). View Institutional Ownership Trends for Rubius Therapeutics.
Which institutional investors are buying Rubius Therapeutics stock?
RUBY stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Baillie Gifford & Co., Artal Group S.A., Capital World Investors, Alliancebernstein L.P., BlackRock Inc., Vanguard Group Inc and Vanguard Group Inc.. View Insider Buying and Selling for Rubius Therapeutics.
How do I buy shares of Rubius Therapeutics?
Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rubius Therapeutics' stock price today?
One share of RUBY stock can currently be purchased for approximately $17.06.
How big of a company is Rubius Therapeutics?
Rubius Therapeutics has a market capitalization of $1.35 billion. Rubius Therapeutics employs 83 workers across the globe.
What is Rubius Therapeutics' official website?
How can I contact Rubius Therapeutics?
Rubius Therapeutics' mailing address is 325 VASSAR STREET SUITE 1A, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]
MarketBeat Community Rating for Rubius Therapeutics (NASDAQ RUBY)
MarketBeat's community ratings are surveys of what our community members think about Rubius Therapeutics and other stocks. Vote "Outperform" if you believe RUBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RUBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
